Dapagliflozin Propanediol Monohydrate
Glycemic control in type 2 diabetes; reduces heart-failure hospitalization and slows chronic kidney disease progression
- CAS No.
- 960404-48-2
- Indication Class
- Metabolic / Endocrine
- Patent Expiry
- Off-patent · 2025 (indicative)
- Therapeutic Area
- Endocrine / Cardio-Renal Metabolism
- Target / Mechanism
- SLC5A2
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- Candidate (In-research)
- Linked Intermediates
- Confirm per inquiry
- Patent Scope
- Compound patent in major markets (EU earlier; US incl. paediatric exclusivity to 2025)
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A cornerstone SGLT2 inhibitor spanning diabetes, heart failure and CKD (triple indication) with substantial global demand; GMP/DMF-ready and ideal for driving API sourcing through finished-dose registration.
Endocrine / Cardio-Renal Metabolism · In research; suited to co-development
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Dapagliflozin is a prescription medication in a class of drugs known as SGLT2 inhibitors. It works by helping the kidneys remove excess sugar from the body through urine, effectively lowering blood sugar levels.
Supply source: Unibest · Dapagliflozin Propanediol Monohydrate, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.